Loomis, Sayles & Company
ALT icon

Loomis, Sayles & Company’s Altimmune ALT Stock Holding History

Loomis, Sayles & Company’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6
Closed -$1K – 913
2017
Q2 		$1K Hold
6
– – ﹤0.01% 920
2017
Q1 		$1K Buy
+6
New +$3.21K ﹤0.01% 931

Other funds holding ALT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
FQ
First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Loomis, Sayles & Company's ALT Position: Q3 2017 in Review

Loomis, Sayles & Company sold out of Altimmune (ALT) in Q3 2017, closing a stake of 6 shares — an estimated $1K sold.

Loomis, Sayles & Company first reported a position in ALT in Q1 2017 and held it in 2 quarters. The position peaked at $1K in Q2 2017. 29 funds tracked by Wall St. Rank hold ALT as of Q3 2017.

  • Loomis, Sayles & Company reported no remaining Altimmune position as of Q3 2017 after selling out during the quarter.
  • Loomis, Sayles & Company sold 6 Altimmune shares in Q3 2017, an estimated $1K.
  • Loomis, Sayles & Company first reported a position in Altimmune in Q1 2017 and held it in 2 quarters.
  • Loomis, Sayles & Company's Altimmune position peaked at $1K in Q2 2017.
  • 29 funds tracked by Wall St. Rank held Altimmune as of Q3 2017.

Based on Loomis, Sayles & Company's 13F filing for Q3 2017, filed 14 Nov 2017.